Kiniksa Pharmaceuticals International (KNSA) EBIT (2017 - 2026)

Kiniksa Pharmaceuticals International has reported EBIT for 10 years, with the latest figure at $29.3 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT rose 120.52% year-over-year to $29.3 million; the trailing twelve-month figure through Mar 2026 stood at $38.3 million (up 342.44% YoY), and the FY2025 full-year result was $22.3 million, up 148.92% from the prior year.
• EBIT for Q1 2026 stood at $29.3 million, up from -$35.1 million in the prior quarter.
• The five-year high for EBIT was $46.4 million in Q3 2022, with the low at -$35.1 million in Q4 2025.
• Historically, EBIT has averaged -$556235.3 across 5 years, with a median of -$3.2 million in 2023.
• Annual changes were most pronounced in 2024 — EBIT plunged 23925.93% — and 2025, when it surged 17330.77%.
• Kiniksa Pharmaceuticals International's EBIT stood at $6.0 million in 2022, then plunged by 98.66% to $81000.0 in 2023, then sank by 23925.93% to -$19.3 million in 2024, then plunged by 82.07% to -$35.1 million in 2025, then surged by 183.29% to $29.3 million in 2026.
• The last three EBIT figures came in at $29.3 million (Q1 2026), -$35.1 million (Q4 2025), and $24.0 million (Q3 2025), per Business Quant data.